Overview
- Revolution Medicines released Phase 3 results presented May 31 showing median overall survival of about 13.2 months with daraxonrasib versus roughly 6.6–6.7 months with chemotherapy, a mortality reduction near 60 percent.
- The FDA has authorized an expanded access pathway and Revolution has begun a rolling New Drug Application with signals of expedited review, allowing eligible patients to receive the drug before formal approval.
- Oncologists report a surge in requests and cancer centers and distributors are processing case‑by‑case applications, creating operational strain and potential inequities in who can get early access.
- Trial data show daraxonrasib is an oral ‘panRAS’ inhibitor that targets multiple KRAS subtypes, had fewer high‑grade toxicities and fewer treatment stoppages than chemo, but experts warn it is not a cure and resistance is expected.
- The result has sparked strong investor interest and plans to test daraxonrasib in other RAS‑driven tumors such as some colorectal and lung cancers, offering both commercial upside and wider clinical research paths.